What is US Stem Cell Financial Strength?
US Stem Cell has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
US Stem Cell did not have earnings to cover the interest expense.
US Stem Cell's debt to revenue ratio for the quarter that ended in Dec. 2022 was 111.84.
As of today, US Stem Cell's Altman Z-Score is 0.00.
Competitive Comparison of US Stem Cell's Financial Strength
For the Biotechnology subindustry, US Stem Cell's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Financial Strength distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Financial Strength falls into.
US Stem Cell Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
US Stem Cell's Interest Expense for the
months ended in Dec. 2022 was $-0.19 Mil. Its Operating Income for the
months ended in Dec. 2022 was $-0.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.68 Mil.
US Stem Cell's Interest Coverage for the quarter that ended in Dec. 2022 is
| US Stem Cell did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
US Stem Cell's Debt to Revenue Ratio for the quarter that ended in Dec. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
US Stem Cell has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (US Stem Cell) Business Description
Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
| Murphy William P Jr |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Gregory Knutson |
director |
14855 ABERDEN STREET NE, HAM LAKE MN 55304 |
| Mark P Borman |
director |
5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410 |
| Charles A Hart |
director |
19345 RHINESTONE STREET NW, ANOKA MN 55303 |
| Sheldon T. Anderson |
director |
1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149 |
| Kristin C Comella |
officer: Chief Science Officer |
1310 LEEWARD WAY, WESTON FL 33327 |
| A Jones Lee |
director |
54 LOCKE LAKE RD, FRIDLEY MN 55432 |
| Karl Groth |
director |
1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029 |
| Matthew J Fendrich |
officer: Vice President,Sales&Marketing |
482 PEACOCK LANE SOUTH, JUPITER FL 33458 |
| Alan P Timmins |
director |
1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
| Bruce C Carson |
director |
11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448 |
| Howard J Leonhardt |
director, 10 percent owner, officer: Executive Chairman & CTO |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Bromley R Scott |
officer: VP of Public Relations |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Richard Iii Spencer |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Mike Tomas |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
US Stem Cell (US Stem Cell) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your